MedPath

PFIZER INC.

PFIZER INC. logo
🇺🇸United States
Ownership
Public
Established
1849-01-01
Employees
88K
Market Cap
$163.3B
Website
http://www.pfizer.com
Clinical Trials
Related News

A Study to Evaluate the Pharmacokinetics, Pharmacodynamics, Safety and Tolerability of PF-06882961 in Chinese Adults With Type 2 Diabetes Mellitus

Phase 1
Completed
Conditions
Diabetes Mellitus, Type 2
Interventions
Drug: Placebo
First Posted Date
2021-05-17
Last Posted Date
2024-09-30
Lead Sponsor
Pfizer
Target Recruit Count
20
Registration Number
NCT04889157
Locations
🇨🇳

Peking University Third Hospital, Beijing, China

A Post-marketing Surveillance to Assess the Safety and Effectiveness of Zirabev in Domestic Patients With Various Cancer

Withdrawn
Conditions
Metastatic Kidney Cancer
Epithelial Ovarian Cancer
Non-small Cell Lung Cancer
Metastatic Colorectal Cancer
Cervical Cancer
Metastatic Breast Cancer
Fallopian Tube Cancer
Primary Peritoneal Cancer
Interventions
First Posted Date
2021-05-17
Last Posted Date
2025-03-19
Lead Sponsor
Pfizer
Target Recruit Count
400
Registration Number
NCT04889495

Safety and Immunogenicity Study of 20vPnC When Coadministered With a Booster Dose of BNT162b2

Phase 3
Completed
Conditions
Pneumococcal Disease
SARS-CoV-2 Infection
COVID-19
Interventions
Biological: 20-valent pneumococcal conjugate vaccine (20vPnC)
Biological: BNT162b2
Other: Saline
First Posted Date
2021-05-14
Last Posted Date
2022-12-14
Lead Sponsor
Pfizer
Target Recruit Count
570
Registration Number
NCT04887948
Locations
🇺🇸

Aventiv Research Inc, Columbus, Ohio, United States

🇺🇸

Acevedo Clinical Research Associates, Miami, Florida, United States

🇺🇸

Anaheim Clinical Trials, LLC, Anaheim, California, United States

and more 21 locations

Study to Test the Safety and Tolerability of PF-07257876 in Participants With Selected Advanced Tumors.

Phase 1
Completed
Conditions
Squamous Cell Carcinoma of the Head and Neck
Ovarian Cancer
Non-Small Cell Lung Cancer
Interventions
Biological: PF-07257876
First Posted Date
2021-05-11
Last Posted Date
2024-04-03
Lead Sponsor
Pfizer
Target Recruit Count
29
Registration Number
NCT04881045
Locations
🇺🇸

Siteman Cancer Center - St Peters, Saint Peters, Missouri, United States

🇪🇸

Hospital General Universitario Gregorio Marañon, Madrid, Madrid, Comunidad DE, Spain

🇺🇸

The Angeles Clinic and Research Institute, A Cedars-Sinai Affiliate (Emergency Back-Up Only), Santa Monica, California, United States

and more 38 locations

Efficacy and Safety of CAZ-AVI in the Treatment of Infections Due to Carbapenem-resistant G- Pathogens in Chinese Adults

Phase 4
Completed
Conditions
Hospital Acquired Pneumonia
Acute Pyelonephritis
Intra-abdominal Infection
Bacteremia
Urinary Tract Infection
Ventilator-associated Pneumonia
Interventions
Drug: Zavicefta, Ceftazidime-Avibactam
Drug: Best Available Treatment
First Posted Date
2021-05-11
Last Posted Date
2024-10-21
Lead Sponsor
Pfizer
Target Recruit Count
60
Registration Number
NCT04882085
Locations
🇨🇳

Chizhou People's Hospital, Chizhou, Anhui, China

🇨🇳

Shenzhen People's Hospital, Shenzhen, Guangdong, China

🇨🇳

The First Affiliated Hospital of Bengbu Medical, Bengbu, Anhui, China

and more 32 locations

Special Investigation of COMIRNATY in the Population With Underlying Diseases

Completed
Conditions
COVID-19
Interventions
Biological: BNT162b2
First Posted Date
2021-05-10
Last Posted Date
2024-06-21
Lead Sponsor
Pfizer
Target Recruit Count
1075
Registration Number
NCT04880447
Locations
🇯🇵

Pfizer Local County, Tokyo, Japan

Study to Evaluate Safety and Tolerability of a Single Dose of PF-06741086 in Chinese Adult Participants With Severe Hemophilia

Phase 1
Completed
Conditions
Severe Hemophilia
Interventions
Biological: PF-06741086
First Posted Date
2021-05-07
Last Posted Date
2023-07-07
Lead Sponsor
Pfizer
Target Recruit Count
6
Registration Number
NCT04878731
Locations
🇨🇳

Institute of Hematology, Chinese Academy of Medical Sciences, Tianjin, Tianjin, China

Korean Post-marketing Surveillance for Xeljanz XR

Recruiting
Conditions
Active Moderate to Severe Rheumatoid Arthritis
Active Ankylosing Spondylitis
Active Psoriatic Arthritis
First Posted Date
2021-05-06
Last Posted Date
2025-04-16
Lead Sponsor
Pfizer
Target Recruit Count
200
Registration Number
NCT04876781
Locations
🇰🇷

Pfizer, Seoul, Korea, Republic of

20-valent Pneumococcal Conjugate Vaccine Safety and Immunogenicity Study in Pneumococcal Vaccine-Naïve Adults 60 Years of Age and Older in Japan, Korea, and Taiwan

Phase 3
Completed
Conditions
Pneumococcal Disease
Interventions
Other: Saline
First Posted Date
2021-05-06
Last Posted Date
2024-11-05
Lead Sponsor
Pfizer
Target Recruit Count
1425
Registration Number
NCT04875533
Locations
🇯🇵

Seishinkai Inoue Hospital, Itoshima, Fukuoka, Japan

🇯🇵

Medical Corporation Heishinkai OPHAC Hospital, Osaka-shi, Osaka, Japan

🇯🇵

Fukuwa Clinic, Chuo-ku, Tokyo, Japan

and more 25 locations

A Study in Healthy Adult Male Participants to Assess Absorption, Distribution, Metabolism and Excretion (ADME) of Radiolabeled PF-06865571.

Phase 1
Completed
Conditions
Healthy Participants
Interventions
Drug: Oral [14C]PF-06865571
Drug: Oral PF-06865571
Drug: IV [14C]PF-06865571
First Posted Date
2021-04-29
Last Posted Date
2024-07-31
Lead Sponsor
Pfizer
Target Recruit Count
6
Registration Number
NCT04866225
Locations
🇺🇸

Labcorp Clinical Research Unit, Madison, Wisconsin, United States

© Copyright 2025. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy